Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors

Trial Profile

Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telaglenastat (Primary) ; Cabozantinib; Docetaxel; Erlotinib; Everolimus; Paclitaxel
  • Indications Advanced breast cancer; Bone cancer; Colorectal cancer; Gallbladder cancer; Gastric cancer; Gastrointestinal stromal tumours; Liver cancer; Malignant-mesothelioma; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer; Uterine cancer
  • Focus Adverse reactions; First in man
  • Sponsors Calithera Biosciences
  • Most Recent Events

    • 09 Feb 2022 Results evaluating the telaglenastat plus cabozantinib or everolimus, agents known to impair glucose metabolism in patients with metastatic RCC, published in the Clinical Cancer Research.
    • 20 Jul 2021 Results (n=120) assessing the recommended phase 2 dose and evaluate safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity by exploratory tumor-/biomarker-specific cohorts, published in the Clinical Cancer Research.
    • 13 Feb 2020 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top